Gyros appoints Jan Würtz as Chief Executive Officer

02-Jul-2004

Gyros AB announced today the appointment of Mr. Jan Würtz as President and Chief Executive Officer within the company. Mr. Würtz has extensive executive experience gained within the Life Science industry and the diagnostics sector in particular.

Mr. Würtz has over 20 years experience in the Life Science industry, beginning at Gambro Engström AB, where he was appointed Vice President, Marketing and Sales. Since then, Mr. Würtz has held several senior management positions within Pharmacia Biosystems AB, Kabi Pharmacia AB and Pharmacia Diagnostics AB, where he was President and Chief Executive Officer, before joining Decim AB as President and Chief Executive Officer.

During his career, Mr. Würtz has held key roles in several mergers and acquisitions and has a proven track record for implementing restructuring and change programs that focus on revenue growth and profitability.

Mr. Würtz joins Gyros after working most recently as a consultant, focusing on executive management support, Director of Board engagements and venture capital projects.

Commenting on his new appointment, Mr. Würtz said, “This is a very exciting time to be joining Gyros. The company has a very solid technology platform and products that are performing well in the marketplace. Gyros is now entering a new phase, in which we need to build on the current foundation and ensure the long-term commercial success of the company.”


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.